Teva Pharmaceutical Industries

NYSE: TEVA ↗ $31.48 USD ~$15B MCAP

#Generic Medicines #Central Nervous System (CNS) Disorders #Multiple Sclerosis #Immunology #Respiratory #Oncology (generics)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, produces, and markets affordable generic and specialty medicines, with a leading position in generic drugs and a growing specialty portfolio focused on central nervous system disorders, immunology, and respiratory conditions.

Company Info

Sector: Pharmaceutical / Generics and Specialty

Headquarters: Tel Aviv, Israel (US operations: Parsippany, New Jersey)

Founded: 1901

Website: www.tevapharm.com/

Upcoming Milestones & Key Dates

Q2 2026

Earnings

Q1 2026 Earnings — Austedo franchise and generic pipeline update

Mid-2026

Business Development

Expected close of API unit divestiture (subject to finding buyer)

Clinical Development Pipeline

Austedo (deutetrabenazine)

Target: VMAT2 inhibitor

Chorea associated with Huntington's disease and tardive dyskinesia

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Ajovy (fremanezumab)

Target: Anti-CGRP monoclonal antibody

Migraine prevention

Preclinical

Phase 1

Phase 2

Phase 3

Approved

TEV-'248 (generic pipeline)

Target: Various (small molecules and biologics)

Multiple high-value generic launches across oncology, immunology, and CNS

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Teva to Lay Off 250 at For-Sale API Unit: Report ↗

Teva Pharmaceutical Industries is laying off approximately 250 employees at its active pharmaceutical ingredient (API) manufacturing unit, which the company is seeking to divest as part of an ongoing restructuring.

Leadership Team

Richard Francis

President and Chief Executive Officer

Eli Kalif

Executive Vice President and Chief Financial Officer

Dr. Eric Hughes

Executive Vice President, Global R&D and Chief Medical Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →